Microenvironment-induced programmable nanotherapeutics restore mitochondrial dysfunction for the amelioration of non-alcoholic fatty liver disease

Principles of nanoparticle design for overcoming biological barriers to drug delivery

Elvin Blanco, Haifa Shen, Mauro Ferrari · Nature Biotechnology · 2015 · 6.7K citations · Full text

Pharmacy, Biomedical Engineering, Pharmaceutics +16

RETRACTED: Effects of melatonin on fatty liver disease: The role of <scp>NR</scp>4A1/<scp>DNA</scp>‐<scp>PK</scp>cs/p53 pathway, mitochondrial fission, and mitophagy

Hao Zhou, Wenjuan Du, Ye Li et al. · Journal of Pineal Research · 2017 · 296 citations

Life Sciences, Biochemistry, Cell Biology +17

Mitochondrial E3 ligase MARCH5 regulates FUNDC1 to fine‐tune hypoxic mitophagy

Ziheng Chen, Lei Liu, Qi Cheng et al. · EMBO Reports · 2017 · 288 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +12

Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping

Zhipeng Liu, Yang Zhang, Sarah E. Graham et al. · Journal of Hepatology · 2020 · 263 citations · Full text

Medicine, Endocrinology, Molecular Medicine +12

Multistage pH‐Responsive Liposomes for Mitochondrial‐Targeted Anticancer Drug Delivery

Ran Mo, Qiong Sun, Jingwei Xue et al. · Advanced Materials · 2012 · 245 citations

Pharmacy, Oncology, Pharmaceutics +17